AMAG Pharmaceuticals, Inc. Release: Study Showing Effectiveness Of Mugard® For Management Of Oral Mucositis Featured In The Journal Cancer
WALTHAM, Mass., April 28, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that the publication of data from a multi-institutional trial of MuGard has been featured in the print edition of the journal Cancer, available today. MuGard is a mucoadhesive hydrogel that forms a protective coating over the oral mucosa. The randomized, double-blind, placebo-controlled trial showed MuGard was more effective than a sham-control in significantly reducing the mouth and throat soreness associated with oral mucositis, a common and debilitating side effect of radiotherapy used to treat patients with head and neck cancer.
Help employers find you! Check out all the jobs and post your resume.